NAP1L1 and glioblastoma: In recent years, several nanobodies have sprouted against glioblastoma targets of protein biosynthesis (TUFM, TRIM28), DNA metabolism (NAP1L1), and cellular growth (EGFR, DPYSL2, β-Actin)48–50.